Lambin T, Lafon C, Drainville RA, Pioche M, Prat F. Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma. World J Gastroenterol 2022; 28(13): 1288-1303 [PMID: 35645539 DOI: 10.3748/wjg.v28.i13.1288]
Corresponding Author of This Article
Frédéric Prat, MD, Doctor, Service d’Endoscopie Digestive, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, 100 Bd du Général Leclerc, Clichy 92110, France. Frederic.prat@aphp.fr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 7, 2022; 28(13): 1288-1303 Published online Apr 7, 2022. doi: 10.3748/wjg.v28.i13.1288
Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma
Thomas Lambin, Cyril Lafon, Robert Andrew Drainville, Mathieu Pioche, Frédéric Prat
Thomas Lambin, Cyril Lafon, Robert Andrew Drainville, LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, Lyon 69003, France
Thomas Lambin, Mathieu Pioche, Department of Gastroenterology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon 69008, France
Frédéric Prat, Service d’Endoscopie Digestive, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy 92110, France
Frédéric Prat, INSERM U1016, Institut Cochin, Université de Paris, Paris 75014, France
Author contributions: Lambin T and Prat F reviewed the literature and prepared the manuscript; Lafon C, Drainville RA, and Pioche M contributed to and revised the manuscript; all authors approved the final manuscript.
Supported bythe Labex DEVweCan (Université de Lyon) and PCSI ITMO Cancer INSERM.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Frédéric Prat, MD, Doctor, Service d’Endoscopie Digestive, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, 100 Bd du Général Leclerc, Clichy 92110, France. Frederic.prat@aphp.fr
Received: December 7, 2021 Peer-review started: December 7, 2021 First decision: January 27, 2022 Revised: February 10, 2022 Accepted: February 27, 2022 Article in press: February 27, 2022 Published online: April 7, 2022
Core Tip
Core Tip: The prognosis of pancreatic ductal adenocarcinoma is poor, with a 5-year survival rate of approximately 8%. This is mainly due to an unfavorable tumoral microenvironment (tumor vasculature, stroma, and immune response). Locoregional therapies can alleviate some barriers to effective antitumoral treatment. This review explores the action of locoregional treatments on pancreatic cancer, with a specific focus on hyperthermia, radiation therapy, high-intensity focused ultrasound, and irreversible electroporation. After a description of the particularities of the tumoral microenvironment of pancreatic cancer, the effects of these treatments on the tumoral microenvironment and implications for future management of patients are discussed.
